Atlas Trials

A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy

Clinical trial NCT04291781 · COMPLETED

Trial details

NCT number
NCT04291781
Sponsor
RemeGen Co., Ltd.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Primary IgA Nephropathy
Start date
2020-04-13
Primary completion
2021-05-20
Enrollment
44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.